Abiopharma

XILIO THERAPEUTICS, INC. (XLO) Reports the reporting period Financial Results XILIO THERAPEUTICS, INC. (XLO) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 12648
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 150333
  • targeting PSMA and STEAP1 with built-in co-stimulatory signaling. PSMA and STEAP1 are expressed in most prostate cancer tumors, and targeting both TAAs with a single molecule has the potential to address tumor heterogeneity while minimizing the potential for resistance due to antigen escape. Xilio anticipates initiating IND-enabling activities for its PSMA+STEAP1 program in the second quarter of 2026
  • targeting domain and one or more tumor-associated antigen (TAA) binding domains (which may be masked) as part of the core molecule design. Depending on the desired properties that Xilio is seeking to achieve for a particular molecule, Xilio’s modular architecture enables the ability to incorporate a co-stimulatory domain designed to further enhance potency and durability of T cell response, include multiple TAA binding domains and/or also mask the TAA binding domain(s) and/or co-stimulatory signaling domain. Upon tumor-selective activation, Xilio’s TCE molecules are designed to release a potent, short half-life TCE in the tumor microenvironment. •Xilio is advancing XTX601, a potential first-in-class masked TCE targeting CLDN18.2, a TAA expressed in gastrointestinal cancers (gastric, pancreatic and esophageal). In parallel, Xilio is leveraging its modular design architecture to evaluate designs that incorporate masking of the CLDN18.2 binding domain and/or the addition of a co-stimulatory domain. Xilio initiated IND-enabling activities for its CLDN18.2 program in the first quarter of 2026
  • targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028